While we are not refuting this important work by Wang et al. [79], albeit the issue whereby electronic records of patients may yield omissions related to certain diagnostic criteria (e.g., SI and even suicide attempts), we cannot ignore media reports such as the April 17th from the NY Post suggesting that Ozempic appears to be changing a growing number of patients claiming that the GLP1 agonistic medications have caused anxiety, and SI even as they shed the pounds. The gene discussed is GLP1R; the disease is Anxiety.